Bilfinger reported solid Q4 results driven by strong order intake, while Eastern and Ocugen discussed their respective financial positions and clinical pipelines. EyePoint Pharmaceuticals highlighted progress with its key drug, DURAVYU, and its sustained revenue growth.
Comments